Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Feb;65(2):242-5.
doi: 10.1136/ard.2005.040717.

Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen

G J D Hengstman  1 , W T M Vree Egberts, H P Seelig, I E Lundberg, H M Moutsopoulos, A Doria, M Mosca, J Vencovsky, W J van Venrooij, B G M van Engelen
Affiliations
Comparative Study

Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen

G J D Hengstman et al. Ann Rheum Dis. 2006 Feb.

Abstract

Objectives: To assess the clinical implications of autoantibodies directed against different parts of the Mi-2 beta autoantigen in patients with myositis.

Methods: A systematic assessment of the clinical, laboratory, and histological characteristics of 48 anti-Mi-2 positive patients from six European centres was made. Anti-Mi-2 autoantibodies were determined with an ELISA using four overlapping fragments spanning the entire amino acid sequence of the autoantigen. Data were compared with results for a large group of anti-Mi-2 negative patients with myositis published previously.

Results: Anti-Mi-2 autoantibodies were found in dermatomyositis, polymyositis, and inclusion body myositis. In general, myositis with anti-Mi-2 autoantibodies was characterised by relatively mild disease, sometimes accompanied by extra-muscular symptoms, including arthralgia, arthritis, Raynaud's phenomenon, and interstitial lung disease. Cardiac disease was not seen, and treatment response was fair. No differences were found between patients with autoantibodies to different fragments of the Mi-2 beta antigen, except for a potentially increased risk of cancer in patients with antibodies directed to the N-terminal fragment of the autoantigen.

Conclusions: Anti-Mi-2 autoantibodies are not a marker of a specific subtype of myositis. No significant differences between patients with autoantibodies to different fragments of the Mi-2 beta autoantigen are found, with the possible exception of an increased risk of cancer in patients with antibodies to the N-terminal fragment.

PubMed Disclaimer

Conflict of interest statement

Conflict: None of the authors have a conflict of interest to declare.

References

    1. Hengstman G J D, Van Engelen B G M, Vree Egberts W T M, Van Venrooij W J. Myositis specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 200113476–482. - PubMed
    1. Zhang Y, LeRoy G, Seelig H P, Lane W S, Reinberg D. The dermatomyositis‐specific autoantigen Mi‐2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 199895279–289. - PubMed
    1. Targoff I N, Reichlin M. The association between Mi‐2 antibodies and dermatomyositis. Arthritis Rheum 198528796–803. - PubMed
    1. Love L A, Leff R L, Fraser D D, Targoff I N, Dalakas M, Plotz P H.et al A new approach to the classification of idiopathic inflammatory myopathy: myositis‐specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 199170360–374. - PubMed
    1. Hausmanowa‐Petrusewicz I, Kowalska‐Oledzka E, Miller F W, Jarzabek‐Chorzelska M, Targoff I N, Blaszczyk‐Kostanecka M.et al Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997401257–1266. - PubMed

Publication types

MeSH terms